Neil Bander, MD, Founder of Convergent Therapeutics

Neil Bander, MD

Chief Scientific Advisor / Founder

Dr. Neil H. Bander is the Bernard and Josephine Chaus Professor in Urological Oncology and Director of Urological Oncology Research at Weill Cornell Medicine. His team at Weill Cornell Medicine has the world’s largest experience in antibody discovery and clinical development in urological cancers. His group developed the first monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could successfully target prostate cancers in patients. This enabled them to define much of the biology of PSMA and clinically validate PSMA as a target in prostate and other cancers. As a result of Dr. Bander and his team’s pioneering efforts, PSMA has become a target of substantial interest and activity in bio-pharma. 

Dr. Bander is a surgeon-scientist trained in urological oncology and tumor immunology, both at Memorial Sloan Kettering Cancer Center. He has authored approximately 200 peer-reviewed publications, and he is an inventor on approximately 150 US and foreign issued and pending patents. He has served on, and chaired, multiple study sections and grant review panels and received several honors including the FC Valentine Fellowship from the NY Academy of Medicine, the Society of Surgical Oncology James Ewing Research Award, awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clark Medal for Surgical Innovation from the Royal College of Surgeons (London). He also serves on several industry Scientific Advisory Boards.